Jake predicted early that ENTA would go down to its IPO price. Nobody else has provided a price estimate. If the price gets close to the IPO price, but does not reach it, then was Jake correct?
No he didn't make that prediction early. He also never acknowledged that the EDP-235 phase 2 data was impressive and better than Paxlovid as it reduced symptoms in a low risk population whereas Paxlovid failed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.